期刊
FUTURE ONCOLOGY
卷 14, 期 24, 页码 2543-2556出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0087
关键词
alkaline phosphatase; biomarker; bone metastases; castration-resistant prostate cancer; mechanism of action; prognostic marker; survival
类别
资金
- Bayer
- Janssen-Cilag (Johnson Johnson)
- Merck Sharp Dohme
- Roche
- Bayer HealthCare Pharmaceuticals, LLC
- Takeda
- Astellas
- Daiichi-Sankyo
- Pfizer
- Taiho
- Nihon-Kayaku
- Endocyte
- Innocrin
- Johnson Johnson
- Sanofi-Aventis
- Bayer HealthCare Pharmaceuticals
Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据